Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China In 2018: Watch Out For AI, CAR-T And Biotech Unicorns

Executive Summary

Armed with massive amounts of data, China is poised to make a dent in big data-driven innovation and artificial intelligence applications including smart health. A policy push to encourage the development of novel drugs also means there may be more biotech unicorns and innovative therapies to attract investment inflows.

You may also be interested in...



2017 A Takeoff Year For China Drug Approvals?

2017 may become a banner year for the China FDA as the agency officially joined the ICH process and began aligning more closely with the US FDA, approving over 25 innovative new drugs so far with an increasing focus on treatments for cancer, hepatitis and orphan diseases.

Pharma-BAT Digital Health Tango In China: Will It Pay Off?

China's internet giants Baidu, Alibaba and Tencent, collectively called BAT, are increasingly tapping into digital health to benefit from recent policy changes, and 2017 saw pharma companies eagerly jump onboard to share the potential gains.

Bluebird Flies On 100% Response Rate For Anti-BCMA CAR-T

Data from a Phase I trial testing the CAR-T therapy bb2121 in in heavily treated patients with relapsed refractory multiple myeloma were encouraging, driving bluebird's stock up 10%.

Topics

Related Companies

UsernamePublicRestriction

Register

SC100206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel